Home › Funds › Bellevue Group AG › BSX
Bellevue Group AG position in BSX
BOSTON SCIENTIFIC CORP · Health Care
Bellevue Group AG reported holding 827,682 shares of BSX (BOSTON SCIENTIFIC CORP) in its Q3 2026 13F filing — a position valued at US$36.1M, representing 0.75% of its reported portfolio and ranking #34 among its reported holdings. Bellevue Group AG has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's BSX position evolved
Bellevue Group AG first disclosed a stake in BSX in Q3 2023 at 2,646,295 shares (US$139.7M). The position peaked in Q1 2024 at 3,148,676 shares, worth US$215.7M. Across 13 filings, Bellevue Group AG increased the stake 1 time(s), trimmed it 11 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 827,682 shares valued at US$36.1M — a reduction of -59,968 shares quarter over quarter.. Notable position changes include a 39% trim in Q2 2026 (shares rose 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 2.65M | $139.72M | New |
| Q4 2023 | 3.17M | $183.29M | Add |
| Q1 2024 | 3.15M | $215.65M | Reduce |
| Q2 2024 | 2.57M | $197.88M | Reduce |
| Q3 2024 | 2.45M | $205.54M | Reduce |
| Q4 2024 | 2.14M | $190.72M | Reduce |
| Q1 2025 | 1.95M | $196.82M | Reduce |
| Q2 2025 | 1.77M | $189.60M | Reduce |
| Q3 2025 | 1.66M | $162.05M | Reduce |
| Q4 2025 | 1.56M | $148.71M | Reduce |
| Q1 2026 | 1.47M | $92.05M | Reduce |
| Q2 2026 | 887.65K | $37.88M | Reduce |
| Q3 2026 | 827.68K | $36.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BSX and 13F data
BSX (BOSTON SCIENTIFIC CORP) is a Health Care company. 20 other funds we track also report a position in BSX — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$2.56B), MFS Investment Management (US$2.29B), Arrowstreet Capital (US$1.24B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BSX
- PRIMECAP MANAGEMENT CO/CA/ 58.62M sh · $2.56B · Q3 2026
- MFS Investment Management 43.05M sh · $2.29B · Q3 2026
- Arrowstreet Capital 28.47M sh · $1.24B · Q3 2026
- D. E. Shaw & Co 27.27M sh · $1.16B · Q2 2026
- AQR CAPITAL MANAGEMENT LLC 24.32M sh · $1.06B · Q3 2026
- Two Sigma Investments 20.01M sh · $873.30M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held BSX?
Bellevue Group AG has disclosed BSX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in BSX?
As of Q3 2026, Bellevue Group AG holds 827.68K shares of BSX (BOSTON SCIENTIFIC CORP), valued at $36.13M, representing 0.75% of its reported portfolio and ranking #34.
Has Bellevue Group AG been buying or selling BSX?
In the latest 13F filing (Q3 2026), Bellevue Group AG reduced its position in BSX. The position peaked in Q1 2024 at 3.15M shares.
Which other funds hold BSX?
Other major institutional holders of BSX include PRIMECAP MANAGEMENT CO/CA/, MFS Investment Management, Arrowstreet Capital, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.